Compare IRWD & WEST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRWD | WEST |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.8M | 741.4M |
| IPO Year | 2009 | 2022 |
| Metric | IRWD | WEST |
|---|---|---|
| Price | $4.11 | $8.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $7.67 | $7.00 |
| AVG Volume (30 Days) | ★ 2.0M | 400.6K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1400.00 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | $298,276,000.00 | ★ $1,188,952,000.00 |
| Revenue This Year | $57.95 | $11.27 |
| Revenue Next Year | $4.39 | $10.66 |
| P/E Ratio | $7.53 | ★ N/A |
| Revenue Growth | 8.88 | ★ 39.76 |
| 52 Week Low | $1.01 | $3.59 |
| 52 Week High | $5.78 | $10.19 |
| Indicator | IRWD | WEST |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 51.91 |
| Support Level | $3.80 | $7.73 |
| Resistance Level | $4.53 | $8.50 |
| Average True Range (ATR) | 0.27 | 0.42 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 28.36 | 78.84 |
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider mainly in the United States. Additionally, it offers coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice, restaurant, convenience store, travel center, non-commercial account, and hospitality industries around the world. The company's reportable segments are: Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment, which offers beverage solutions, including coffee, tea, flavors, extracts, and ingredients. Geographically, the company generates maximum revenue from its business in the United States and the rest from other countries.